Comparison of relapse rates and of mucosal abnormalities after healing of duodenal ulceration and after one year's maintenance with cimetidine or sucralfate: a light and electron microscopy study
- PMID: 2731750
- PMCID: PMC1434205
- DOI: 10.1136/gut.30.5.586
Comparison of relapse rates and of mucosal abnormalities after healing of duodenal ulceration and after one year's maintenance with cimetidine or sucralfate: a light and electron microscopy study
Abstract
Forty six patients with endoscopically diagnosed duodenal ulceration were randomly allocated to treatment with either sucralfate 1 g qds (n = 24) or cimetidine 200 mg tds and 400 mg nocte (n = 22). When the ulcers healed, a maintenance dose of sucralfate 1 g bd or cimetidine 400 mg nocte was given for one year (or until relapse if earlier). Biopsies of duodenal mucosa adjacent to ulcer sites for light and electron microscopy were obtained before and after healing and again after one year's maintenance if the ulcer remained healed. Duodenal biopsies were also taken from 20 age and sex matched controls. Rates of healing and relapse during maintenance did not differ between the two treatments, although relapses occurred earlier with cimetidine. In the three year post-maintenance follow up period 10/13 cimetidine patients relapsed compared with four of 11 sucralfate patients (p less than 0.05), the relapses occurring significantly earlier in the cimetidine treated patients (p less than 0.05). Mucosal biopsies from both treatment groups still showed considerable abnormalities after healing. During maintenance, however, the sucralfate scores fell significantly (p less than 0.02) to near control levels unlike the cimetidine scores which remained raised at pretreatment values. The histological and ultrastructural changes were not predictive of later relapse. These findings favour the use of sucralfate in preference to cimetidine for maintenance treatment in the prevention of relapse of healed duodenal ulcers.
Similar articles
-
Differences in mucosal appearances and in relapse rates in duodenal ulceration treated with sucralfate or cimetidine.Am J Med. 1989 Jun 9;86(6A):141-4. doi: 10.1016/0002-9343(89)90176-9. Am J Med. 1989. PMID: 2735329 Clinical Trial.
-
Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment.Am J Med. 1992 Mar;92(3):265-74. doi: 10.1016/0002-9343(92)90076-n. Am J Med. 1992. PMID: 1546725 Clinical Trial.
-
Ulcer healing and relapse rates after initial treatment with cimetidine or sucralfate.J Clin Gastroenterol. 1981;3(Suppl 2):163-5. J Clin Gastroenterol. 1981. PMID: 7033353 Clinical Trial.
-
The efficacy, safety and dosage of sucralfate in ulcer therapy.Scand J Gastroenterol Suppl. 1987;140:33-8. Scand J Gastroenterol Suppl. 1987. PMID: 3328283 Review.
-
Medical and surgical prophylaxis for duodenal ulcer, the role of sucralfate.Scand J Gastroenterol Suppl. 1987;127:81-5. Scand J Gastroenterol Suppl. 1987. PMID: 3303296 Review.
Cited by
-
Helicobacter pylori and peptic ulcer recurrence.Gut. 1992 Sep;33(9):1293. doi: 10.1136/gut.33.9.1293-b. Gut. 1992. PMID: 1427385 Free PMC article. No abstract available.
-
Gastric cytoprotection. What does it really mean for the prescriber?Drugs. 1991 Apr;41(4):507-13. doi: 10.2165/00003495-199141040-00001. Drugs. 1991. PMID: 1711956 Review. No abstract available.
-
Acid and gastric metaplasia in the duodenum.Gut. 1995 Jan;36(1):154. doi: 10.1136/gut.36.1.154-a. Gut. 1995. PMID: 7890227 Free PMC article. No abstract available.
-
Relation between gastric acid output, Helicobacter pylori, and gastric metaplasia in the duodenal bulb.Gut. 1996 Oct;39(4):513-20. doi: 10.1136/gut.39.4.513. Gut. 1996. PMID: 8944558 Free PMC article.
-
Gastric metaplasia and Helicobacter pylori infection.Gut. 1996 Jan;38(1):154. doi: 10.1136/gut.38.1.154-a. Gut. 1996. PMID: 8566848 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources